According to the latest estimates from the World Health Organization (WHO), there are more than 80 biotechnology platform-based COVID-19 vaccine candidates in various stages of clinical development. 2 Owing to their inherent characteristics of being robust and flexible, the platform-based smart vaccine development technique has gained much popularity among biopharma companies.
It is worthwhile noting that these platform-based vaccines do not involve the injection of pathogens into the human body, as with traditional vaccines, but instead integrate the genetic sequence information of the disease-causing pathogens. Vaccines based on the two novel biotechnology platform-based techniques mRNA (messenger RNA) and viral vector, have proven successful in controlling the spread of the COVID-19 pandemic.
2 Novel biotechnology platforms for vaccine development This motivated the biopharma sector to devise smart approaches to develop and manufacture vaccines without compromising on their safety and efficacy. However, the biopharma industries realised that traditional vaccine development and manufacturing techniques, which take around five to 10 years for initial development to large-scale distribution, 1 were inadequate to meet the growing demand for COVID-19 vaccines. THE GLOBAL outbreak of the COVID-19 pandemic triggered an urgent need to protect people’s lives and livelihoods and the healthcare community recognised quite early that vaccines were the best solution to this crisis.
0 kommentar(er)
